rph, you wrote: "Another idea that I'll run by everyone... most people I've seen comment seem to think Vibex QS M is scopolamine. Why would they advertise it in their pipeline even though they have not been granted the rights to it yet? Makes no sense for a reputable company to count their chickens before they hatch."
Not sure about what you wrote. Why would they advertise it in their pipeline...? They aren't as far as what I've seen, they only state QS M (neurology). And we won't know what it is until they get this out of preclinical and into the clinical trials.
Also for a clarification is anyone saw my post on ymb (3rd post in a series) when I mentioned the PFE / Antares clinical trial. It looks like very soon after I reviewed the trial for the 5% gel and the latest date of August, they updated the trial date to September. But importantly, they are still in the "enrollment" phase. I expect another payment from Pfizer when enrollment is completed or at least I hope that is the case.
News 
Market Data 
Discover 
AI
